Valeant Pharmaceuticals International Inc. jumped 6.5% in premarket action on Friday after the U.S. Food and Drug Administration late Thursday approved the company’s Vyzulta drug. The drug, a treatment for open angle glaucoma, has been developed by Valeant’s wholly-owned subsidiary Bausch + Lomb and France’s Nicox SA . Shares of Nicox soared 26% in Paris. “We expect to make this new advancement available for those who suffer with glaucoma before the end of the year,” said Joseph C. Papa, Valeant’s chairman and CEO, in a press release.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News